Welcome to
On Feet Nation
The global Veterinary Dermatology Drugs Market is expected to reach USD 28.69 billion by 2030, registering a CAGR of 8.89% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is driven by increasing pet expenditure, humanization of pets, robust R&D pipeline, launch of new products, the prevalence of dermatologic conditions, and initiatives by key companies. For example, in June 2023, Zoetis received FDA clearance for Apoquel Chewable— the country’s first and only chewable pharmaceutical for controlling allergic itch and inflammation in dogs. This expanded the company’s portfolio and supported its growth objectives.
The COVID-19 pandemic and macroeconomic headwinds from 2020 to 2022 had both positive and negative impacts on the market. This included operational challenges, supply chain disruption, limited access to veterinary care, spike in pet adoption, adoption of telemedicine, and increased penetration of pet insurance. Vimian for instance, reported dampened growth during Q1 2022 in its dermatology & specialty care segments due to volatility in shipments between quarters. By Q3 2022, the company reported robust growth in Dermatology & Specialty Care segments. Zoetis on the other hand witnessed volume growth of 14%, 3%, and 9% from in-line portfolio, including its dermatology products during Q2, Q3, and Q4 2021 respectively. In 2022, however, Zoetis reported 1-2% volume growth in its dermatology portfolio every quarter.
Ongoing research and development efforts in the field of veterinary dermatology have led to the creation of more effective and user-friendly drug formulations. These formulations are often easier to administer and can provide quicker relief for pets, ensuring medication compliance. Growing initiatives by key market players is expected to propel the R&D pipeline and promote the launch of new products in the market. In May 2023, Dechra Pharmaceuticals PLC for example, partnered with ILC Therapeutics in Scotland to research and develop the latter’s Caniferon product for the treatment of atopic dermatitis in dogs. This added to the company’s product pipeline.
List of Key Players of Veterinary Dermatology Drugs Market
Related Press Release@ Veterinary Dermatology Drugs Market Report
Veterinary Dermatology Drugs Market Report Highlights
Report Attribute |
Details |
Market size value in 2023 |
USD 15.80 billion |
Revenue forecast in 2030 |
USD 28.69 billion |
Growth rate |
CAGR of 8.89% from 2023 to 2030 |
Base year for estimation |
2022 |
Request For A Free Consultation @ https://www.grandviewresearch.com/request-free-consultation/451973/rfc
Veterinary Dermatology Drugs Market Segmentation
Grand View Research has segmented the global veterinary dermatology drugs market based on indication, type, animal type, route of administration, distribution channel, and region:
Veterinary Dermatology Drugs Indication Outlook (Revenue, USD Million, 2018 - 2030)
Veterinary Dermatology Drugs Type Outlook (Revenue, USD Million, 2018 - 2030)
Veterinary Dermatology Drugs Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
Veterinary Dermatology Drugs Route Of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Veterinary Dermatology Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Veterinary Dermatology Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)
© 2025 Created by PH the vintage.
Powered by
You need to be a member of On Feet Nation to add comments!
Join On Feet Nation